Phase 1 trial of once-weekly eloralintide shows weight reduction in obesity over 12 weeks
Can a new weekly injection help people lose weight? Early results show promise
A Phase 1 randomised controlled trial in 100 participants with obesity or overweight found that once-weekly subcutaneous eloralintide result…
A new weekly shot helped people with obesity lose between 2.6% and 11.3% of their body weight in early safety testing, though larger studies…
GLP-1RAs associated with improved walking distance in diabetes with PAD, but limb event evidence uncertain
GLP-1 drugs linked to better walking distance in diabetes patients with leg artery disease
A meta-analysis of 7 studies (107,092 adults with type 2 diabetes and PAD) found GLP-1RAs were associated with improved walking distance in …
GLP-1 diabetes drugs linked to better walking distance in people with leg artery disease, based on analysis of seven studies involving over …
Bariatric surgery associated with lower cardiovascular risks than GLP-1RA therapy in adults with obesity
Study finds bariatric surgery linked to lower heart risks than GLP-1 drugs in adults with obesity
A meta-analysis of observational studies including 39,569 adults with obesity found bariatric surgery was associated with lower risks of mor…
Adults with obesity who had bariatric surgery faced lower risks of death and heart failure than those taking GLP-1 drugs like Wegovy.
Systematic review maps gut microbiome–epigenetic crosstalk in obesity and type 2 diabetes
What's happening in your gut that might affect your weight and blood sugar?
A systematic review and bibliometric analysis of over 1,100 documents identified three major epigenetic domains involved in gut microbiome c…
Gut bacteria changes linked to obesity and type 2 diabetes may influence genetic switches, with research in this area growing nearly 28% ann…